Iomedico Ag

This study follows 200 adults with polycythemia vera (a blood cancer causing too many red blood cells) who are taking ropeginterferon alfa-2b in real-world German clinics. Researchers will track patients' symptom burden, how well the drug controls blood counts, and safety over th…

This study aims to learn how the drug vorasidenib affects the daily lives and well-being of adults with a specific type of slow-growing brain tumor (IDH-mutant grade 2 glioma) in real-world German clinics. It will follow 150 patients who are already prescribed this drug after sur…

This study aims to understand how the drug zanubrutinib works for adults with certain blood cancers in everyday clinic settings, not a controlled trial. It will follow about 705 patients to see how the treatment affects their quality of life, how often they need hospital care, an…

This study is collecting real-world information on how well the targeted drug ivosidenib works for people with advanced bile duct cancer who have a specific genetic mutation (IDH1 R132) and have already tried at least one other treatment. Researchers will follow 100 patients in G…

This study is creating a national patient registry in Germany to track how people with myelofibrosis (a bone marrow cancer) and anemia are treated in real-world clinics. It will follow 200 patients for up to three years to document which treatments they receive, in what order, an…

This study is creating a national registry to track how nearly 3000 people in Germany with various blood cancers are treated in real-world settings. It will document what treatments patients receive, how they respond, and how their quality of life is affected over time. The goal …

This study is a national registry that aims to collect information on how patients with advanced stomach or esophageal cancer are actually treated in everyday practice in Germany. It will follow about 1,900 patients for up to two years to understand common treatment sequences and…

This study is a national registry that will follow nearly 2,000 patients in Germany with advanced ovarian or endometrial cancer for up to three years. Its purpose is to document the real-world treatments patients receive, track how the disease progresses, and measure their qualit…

This study is creating a national registry to track how multiple myeloma is treated in Germany. It will follow 2,200 patients for up to five years to document their treatments, outcomes, and quality of life. The goal is to understand real-world treatment patterns and collect data…

This study is a national registry that will follow nearly 2,000 patients in Germany with advanced kidney or bladder cancer. Its purpose is to document the real-world treatments patients receive, track how the disease progresses, and measure patients' quality of life over time. Th…